Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marcela Valderrama Maus, M.D., Ph.D.

Title
Institution
Department
Address
Phone

Mentoring
Characterization of Dexamethasone Suppression of Chimeric Antigen Receptor (CAR) T Cells Targeting Glioblastoma Multiforme
Full Time/Year Long, 09/01/17 - 06/30/18
Targeting Tumor Heterogeneity in the Treatment of Glioblastoma Multiforme (GBM) Using BiTE-Secreting EGFRvIII CAR T-cells
Soma Weiss, 09/01/17 - 03/30/19

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA238268 (MAUS, MARCELA VALDERRAMA) Sep 20, 2019 - Aug 31, 2024
    NIH/NCI
    Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies
    Role: Principal Investigator
  2. K08CA166039 (MAUS, MARCELA VALDERRAMA) Sep 19, 2012 - Aug 31, 2017
    NIH/NCI
    Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Maus MV, Lionakis MS. Infections associated with the new 'nibs and mabs' and cellular therapies. Curr Opin Infect Dis. 2020 Aug; 33(4):281-289. PMID: 32657964.
    Citations:    
  2. Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Jul 15; JCO1902103. PMID: 32667831.
    Citations:    
  3. Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy. Neuro Oncol. 2020 Jul 02. PMID: 32615600.
    Citations:    
  4. Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK. Publisher Correction: Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2020 Jul; 38(7):901. PMID: 32541959.
    Citations:    
  5. Maryamchik E, Gallagher KME, Preffer FI, Kadauke S, Maus MV. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry B Clin Cytom. 2020 Jul; 98(4):299-327. PMID: 32352629.
    Citations:    
  6. Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care. 2020 Aug; 58:58-64. PMID: 32361219.
    Citations:    
  7. Weber EW, Maus MV, Mackall CL. The Emerging Landscape of Immune Cell Therapies. Cell. 2020 Apr 02; 181(1):46-62. PMID: 32243795.
    Citations:    
  8. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020 Apr 01; 130(4):1586-1594. PMID: 32235098.
    Citations:    
  9. Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1). PMID: 32300051.
    Citations:    
  10. Scarfò I, Maus MV. Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells. Cancer Cell. 2020 02 10; 37(2):143-144. PMID: 32049043.
    Citations:    
  11. Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 Jan 14; 4(1):106-111. PMID: 31905241.
    Citations:    
  12. Maus MV, Leick MB, Cornejo KM, Nardi V. Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. N Engl J Med. 2019 Nov 14; 381(20):1951-1960. PMID: 31722157.
    Citations:    
  13. Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019 11 14; 7(1):304. PMID: 31727131.
    Citations:    
  14. Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 11 12; 3(21):3248-3260. PMID: 31698455.
    Citations:    
  15. Mondal N, Silva M, Castano AP, Maus MV, Sackstein R. Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. J Biol Chem. 2019 11 29; 294(48):18465-18474. PMID: 31628196.
    Citations:    
  16. Resar LM, Jaffee EM, Armanios M, Jackson S, Azad NS, Horton MR, Kaplan MJ, Laiho M, Maus MV, Sumner CJ, Wheelan SJ, Wills-Karp M. Equity and diversity in academic medicine: a perspective from the JCI editors. J Clin Invest. 2019 10 01; 129(10):3974-3977. PMID: 31524636.
    Citations:    
  17. Wang X, Scarfò I, Schmidts A, Toner M, Maus MV, Irimia D. Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. Adv Sci (Weinh). 2019 Dec; 6(23):1901829. PMID: 31832320.
    Citations:    
  18. Mylvaganam G, Yanez AG, Maus M, Walker BD. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Front Immunol. 2019; 10:2109. PMID: 31552045.
    Citations:    
  19. Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clin Infect Dis. 2019 08 30; 69(6):909-920. PMID: 30520987.
    Citations:    Fields:    
  20. Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clin Cancer Res. 2019 12 01; 25(23):7046-7057. PMID: 31439577.
    Citations:    
  21. Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 09; 37(9):1049-1058. PMID: 31332324.
    Citations:    
  22. Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019 09 12; 134(11):860-866. PMID: 31320380.
    Citations:    
  23. Li M, Chin LY, Shukor S, Tamayo AG, Maus MV, Parekkadan B. Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression. Autoimmunity. 2019 05; 52(3):102-107. PMID: 31238751.
    Citations:    
  24. Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol. 2019 12; 37(12):1425-1434. PMID: 31160723.
    Citations:    
  25. Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, Scarfo I, Choudhary R, Kiner O, Krishnamurthy J, Le B, Morath A, Baldeviano GC, Quinn J, Tavares P, Wei Q, Weiler S, Maus MV, Getts D, Schamel WW, Hofmeister R. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat Commun. 2019 05 07; 10(1):2087. PMID: 31064990.
    Citations:    
  26. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 05 02; 380(18):1726-1737. PMID: 31042825.
    Citations:    
  27. Scarfò I, Frigault MJ, Maus MV. CAR-Based Approaches to Cutaneous T-Cell Lymphoma. Front Oncol. 2019; 9:259. PMID: 31058076.
    Citations:    
  28. Leick M, Maus MV. Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer. Cancer Discov. 2019 Apr; 9(4):466-468. PMID: 30936218.
    Citations:    
  29. Boroughs AC, Larson RC, Choi BD, Bouffard AA, Riley LS, Schiferle E, Kulkarni AS, Cetrulo CL, Ting D, Blazar BR, Demehri S, Maus MV. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight. 2019 03 14; 5. PMID: 30869654.
    Citations:    
  30. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221. PMID: 30808634.
    Citations:    
  31. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2019 02 21; 4(4). PMID: 30830874.
    Citations:    
  32. Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2019 03; 37(3):276-282. PMID: 30742127.
    Citations:    
  33. Leick MB, Maus MV. CAR-T cells beyond CD19, UnCAR-Ted territory. Am J Hematol. 2019 05; 94(S1):S34-S41. PMID: 30632631.
    Citations:    Fields:    
  34. Guedan S, Calderon H, Posey AD, Maus MV. Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019 Mar 15; 12:145-156. PMID: 30666307.
    Citations:    
  35. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 04; 25(4):625-638. PMID: 30592986.
    Citations:    Fields:    
  36. Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018 12 04; 6(1):137. PMID: 30514386.
    Citations:    
  37. Li M, Chin LY, Shukor S, Tamayo A, Maus MV, Parekkadan B. Closed loop bioreactor system for the ex vivo expansion of human T cells. Cytotherapy. 2019 01; 21(1):76-82. PMID: 30497956.
    Citations:    Fields:    
  38. Choi BD, Maus MV, June CH, Sampson JH. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clin Cancer Res. 2019 04 01; 25(7):2042-2048. PMID: 30446589.
    Citations:    Fields:    
  39. Schmidts A, Maus MV. Making CAR T Cells a Solid Option for Solid Tumors. Front Immunol. 2018; 9:2593. PMID: 30467505.
    Citations:    
  40. Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018 10 04; 132(14):1495-1506. PMID: 30089630.
    Citations:    Fields:    
  41. Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie YQ, Li N, Kudchodkar SB, Wong HC, Jeng EK, Maus MV, Irvine DJ. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018 09; 36(8):707-716. PMID: 29985479.
    Citations: 1     Fields:    
  42. Aijaz A, Li M, Smith D, Khong D, LeBlon C, Fenton OS, Olabisi RM, Libutti S, Tischfield J, Maus MV, Deans R, Barcia RN, Anderson DG, Ritz J, Preti R, Parekkadan B. Biomanufacturing for clinically advanced cell therapies. Nat Biomed Eng. 2018 06; 2(6):362-376. PMID: 31011198.
    Citations:    
  43. Maus MV. Tumour tamed by transfer of one T cell. Nature. 2018 06; 558(7709):193-195. PMID: 29895908.
    Citations:    Fields:    Translation:HumansCells
  44. Choi BD, Curry WT, Carter BS, Maus MV. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. Neurosurg Focus. 2018 06; 44(6):E13. PMID: 29852773.
    Citations:    Fields:    
  45. Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-ß Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018 07 05; 26(7):1855-1866. PMID: 29807781.
    Citations: 4     Fields:    
  46. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018 04 19; 3(8). PMID: 29669947.
    Citations: 1     Fields:    
  47. Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Pract Res Clin Haematol. 2018 06; 31(2):158-165. PMID: 29909916.
    Citations:    Fields:    
  48. Choi BD, O'Rourke DM, Maus MV. Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma. J Target Ther Cancer. 2017 Aug; 6(4):22-25. PMID: 29167820.
    Citations:    
  49. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 07 19; 9(399). PMID: 28724573.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  50. Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 01; 127(8):3052-3064. PMID: 28714866.
    Citations: 6     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  51. Sampson JH, Maus MV, June CH. Immunotherapy for Brain Tumors. J Clin Oncol. 2017 Jul 20; 35(21):2450-2456. PMID: 28640704.
    Citations: 5     Fields:    Translation:Humans
  52. Maus MV, Nikiforow S. The Why, what, and How of the New FACT standards for immune effector cells. J Immunother Cancer. 2017; 5:36. PMID: 28428885.
    Citations: 3     Fields:    Translation:Humans
  53. Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. J Immunother. 2017 04; 40(3):104-107. PMID: 28234665.
    Citations: 11     Fields:    Translation:HumansCells
  54. Ormhøj M, Bedoya F, Frigault MJ, Maus MV. CARs in the Lead Against Multiple Myeloma. Curr Hematol Malig Rep. 2017 04; 12(2):119-125. PMID: 28233151.
    Citations: 1     Fields:    Translation:HumansCells
  55. Scarfò I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017; 5:28. PMID: 28331617.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  56. Maus MV. Immunology: T-cell tweaks to target tumours. Nature. 2017 03 02; 543(7643):48-49. PMID: 28225762.
    Citations:    Fields:    Translation:HumansCells
  57. Bedoya F, Frigault MJ, Maus MV. The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Mol Ther. 2017 02 01; 25(2):314-320. PMID: 28153085.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  58. Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncolytics. 2016; 3:1-9. PMID: 29675462.
    Citations: 1     
  59. Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016; 14:357-362. PMID: 27761200.
    Citations: 13     
  60. Maus MV, June CH. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res. 2016 Apr 15; 22(8):1875-84. PMID: 27084741.
    Citations: 41     Fields:    Translation:HumansAnimals
  61. Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfus Med Rev. 2016 07; 30(3):139-45. PMID: 27067907.
    Citations: 1     Fields:    Translation:HumansCells
  62. Frigault MJ, Maus MV. Chimeric antigen receptor-modified T cells strike back. Int Immunol. 2016 07; 28(7):355-63. PMID: 27021308.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  63. Maus MV, Levine BL. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist. 2016 05; 21(5):608-17. PMID: 27009942.
    Citations: 5     Fields:    Translation:HumansCells
  64. Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol. 2016 06; 40:24-35. PMID: 26963133.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  65. Fraietta JA, Schwab RD, Maus MV. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol. 2016 Apr; 43(2):291-9. PMID: 27040708.
    Citations: 1     Fields:    Translation:HumansCells
  66. Maus MV. Innate immune signaling in CLL. Blood. 2016 Jan 28; 127(4):376-8. PMID: 26823508.
    Citations:    Fields:    Translation:Humans
  67. Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016 06 01; 22(11):2684-96. PMID: 26819453.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  68. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar 03; 127(9):1117-27. PMID: 26813675.
    Citations: 37     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  69. Miller BC, Maus MV. CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies. Oncol Res Treat. 2015; 38(12):683-90. PMID: 26633875.
    Citations: 4     Fields:    Translation:HumansCells
  70. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016 05; 30(3):157-67. PMID: 26574053.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  71. Maus MV, Powell DJ. Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity. Cancer J. 2015 Nov-Dec; 21(6):475-9. PMID: 26588679.
    Citations: 5     Fields:    Translation:Humans
  72. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015 Sep 10; 373(11):1040-7. PMID: 26352815.
    Citations: 100     Fields:    Translation:HumansCTClinical Trials
  73. Maus MV. Designing CAR T cells for glioblastoma. Oncoimmunology. 2015 Dec; 4(12):e1048956. PMID: 26587317.
    Citations: 7     
  74. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18; 7(275):275ra22. PMID: 25696001.
    Citations: 80     Fields:    Translation:HumansAnimals
  75. June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014 Sep; 63(9):969-75. PMID: 24943274.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  76. Maus MV, June CH. CARTs on the road for myeloma. Clin Cancer Res. 2014 Aug 01; 20(15):3899-901. PMID: 24919574.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  77. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014 Apr 24; 123(17):2625-35. PMID: 24578504.
    Citations: 158     Fields:    Translation:HumansCells
  78. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014 Feb; 2(2):112-20. PMID: 24579088.
    Citations: 157     Fields:    Translation:HumansCellsCTClinical Trials
  79. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014; 32:189-225. PMID: 24423116.
    Citations: 79     Fields:    Translation:HumansAnimalsCells
  80. Garfall AL, Fraietta JA, Maus MV. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discov Med. 2014 Jan; 17(91):37-46. PMID: 24411699.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  81. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013 Jul; 1:26-31. PMID: 24432303.
    Citations: 57     Fields:    
  82. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013 Aug 08; 122(6):863-71. PMID: 23770775.
    Citations: 220     Fields:    Translation:HumansCells
  83. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013 Jul; 1(1):26-31. PMID: 24777247.
    Citations: 39     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  84. Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):1917-9. PMID: 23444214.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  85. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, Zhou S, Murphy SL, Maus MV, Mingozzi F, Orange JS, High KA. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest. 2009 Jun; 119(6):1688-95. PMID: 19436115.
    Citations: 57     Fields:    Translation:HumansCells
  86. Maus MV, Posencheg MA, Geddes K, Elkan M, Peñaranda S, Oberste MS, Hodinka RL. Detection of echovirus 18 in human breast milk. J Clin Microbiol. 2008 Mar; 46(3):1137-40. PMID: 18199781.
    Citations: 3     Fields:    Translation:HumansCells
  87. Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, Mackall CL. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007 Oct 01; 179(7):4910-8. PMID: 17878391.
    Citations: 59     Fields:    Translation:HumansCells
  88. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, Ragni MV, Manno CS, Sommer J, Jiang H, Pierce GF, Ertl HC, High KA. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007 Apr; 13(4):419-22. PMID: 17369837.
    Citations: 211     Fields:    Translation:HumansAnimalsCells
  89. Maus MV, Kovacs B, Kwok WW, Nepom GT, Schlienger K, Riley JL, Allman D, Finkel TH, June CH. Extensive replicative capacity of human central memory T cells. J Immunol. 2004 Jun 01; 172(11):6675-83. PMID: 15153483.
    Citations: 12     Fields:    Translation:HumansCells
  90. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med. 2003 May; 9(5):619-24. PMID: 12704385.
    Citations: 79     Fields:    Translation:HumansCells
  91. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res. 2003 Apr; 9(4):1517-27. PMID: 12684428.
    Citations: 25     Fields:    Translation:HumansCells
  92. Maus MV, Riley JL, Kwok WW, Nepom GT, June CH. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunol. 2003 Jan; 106(1):16-22. PMID: 12584046.
    Citations: 14     Fields:    Translation:HumansCells
  93. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol. 2002 Dec; 105(3):259-72. PMID: 12498807.
    Citations: 25     Fields:    Translation:HumansCells
  94. Kovacs B, Maus MV, Riley JL, Derimanov GS, Koretzky GA, June CH, Finkel TH. Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):15006-11. PMID: 12419850.
    Citations: 10     Fields:    Translation:HumansCells
  95. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002 Feb; 20(2):143-8. PMID: 11821859.
    Citations: 102     Fields:    Translation:HumansCells
  96. Cosar CB, Cohen EJ, Rapuano CJ, Maus M, Penne RP, Flanagan JC, Laibson PR. Tarsorrhaphy: clinical experience from a cornea practice. Cornea. 2001 Nov; 20(8):787-91. PMID: 11685052.
    Citations: 9     Fields:    Translation:Humans
  97. Bernardino CR, Davidson RS, Maus M, Spaeth GL. Angle-closure glaucoma in association with orbital pseudotumor. Ophthalmology. 2001 Sep; 108(9):1603-6. PMID: 11535457.
    Citations: 2     Fields:    Translation:Humans
  98. Shanno G, Maus M, Bilyk J, Schwartz S, Savino P, Simeone F, Goldman HW. Image-guided transorbital roof craniotomy via a suprabrow approach: a surgical series of 72 patients. Neurosurgery. 2001 Mar; 48(3):559-67; discussion 567-8. PMID: 11270546.
    Citations: 7     Fields:    Translation:Humans
  99. Rubin PA, Fay AM, Remulla HD, Maus M. Ophthalmic plastic applications of acellular dermal allografts. Ophthalmology. 1999 Nov; 106(11):2091-7. PMID: 10571342.
    Citations: 5     Fields:    Translation:Humans
  100. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology. 1999 Nov; 140(11):5447-50. PMID: 10537179.
    Citations: 42     Fields:    Translation:HumansCells
  101. Maus M, Goldman HW. Removal of orbital apex hemangioma using new transorbital craniotomy through suprabrow approach. Ophthalmic Plast Reconstr Surg. 1999 May; 15(3):166-70. PMID: 10355834.
    Citations: 3     Translation:Humans
  102. Aldave AJ, Maus M, Rubin PA. Advances in the management of lower eyelid retraction. Facial Plast Surg. 1999; 15(3):213-24. PMID: 11816084.
    Citations: 1     Fields:    Translation:Humans
  103. Zobian J, Maus M. Thyroid-related ophthalmology. Curr Opin Ophthalmol. 1998 Dec; 9(6):105-10. PMID: 10387329.
    Citations:    Fields:    Translation:Humans
  104. Dei Cas R, Maus M, Bilyk J, Chang W, Eagle RC, Rubin P. Gore-Tex as an orbital implant material. Ophthalmic Plast Reconstr Surg. 1998 Nov; 14(6):425-31. PMID: 9842562.
    Citations:    Translation:AnimalsCells
  105. Rubin PA, Popham J, Rumelt S, Remulla H, Bilyk JR, Holds J, Mannor G, Maus M, Patrinely JR. Enhancement of the cosmetic and functional outcome of enucleation with the conical orbital implant. Ophthalmology. 1998 May; 105(5):919-25. PMID: 9593398.
    Citations: 2     Fields:    Translation:Humans
  106. Neuenschwander MC, Pribitkin E, Lacombe V, Maus M, Rao V, Roth M. Frontoethmoid mucocele complicating Graves' ophthalmopathy. Ann Otol Rhinol Laryngol. 1998 May; 107(5 Pt 1):433-5. PMID: 9596224.
    Citations: 1     Fields:    Translation:Humans
  107. Taylor A, Brown DP, Kadam S, Maus M, Kohlbrenner WE, Weigl D, Turon MC, Katz L. High-level expression and purification of mature HIV-1 protease in Escherichia coli under control of the araBAD promoter. Appl Microbiol Biotechnol. 1992 May; 37(2):205-10. PMID: 1368241.
    Citations:    
  108. Maus M, Katz LJ. Choroidal detachment, flat anterior chamber, and hypotony as complications of neodymium: YAG laser cyclophotocoagulation. Ophthalmology. 1990 Jan; 97(1):69-72. PMID: 2179798.
    Citations: 10     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Maus's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (361)
Explore
_
Co-Authors (69)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.